Therapeutic drug monitoring of TNFinhibitors and other therapeutic antibodies.
Develop assays for novel immunotherapy drugs such as pembrolizumab, nivolumab and ipilimumab for monitoring drug levels in patients with lung cancer and malignant melanoma.
Develop assays for measuring rituximab and anti-rituximab for monitoring drug level and anti-drug antibody formation.
Detection of antibodies to transglutaminase in the HUNT4-cohort using an in-house dual label assay in collaborative study “Coeliac disease in HUNT”.
Screening for patient antibodies to HH1, a novel antibody-based drug used in lymphoma clinical trials (Lymrit).